| 1 | Epidemiological, clinical and genomic insights into the ongoing diphtheria outbreak in |
|----|--|
| 2 | Yemen |
| 3 | |
| 4 | Edgar Badell1,2, Abdulilah Alharazi3, Alexis Criscuolo4, The NCPHL diphtheria outbreak |
| 5 | working group#, Noemie Lefrancq5, Valerie Bouchez1, Julien Guglielmini4, Melanie |
| 6 | Hennart1,6, Annick Carmi-Leroy1,2, Nora Zidane1, Marine Pascal-Perrigault1, Manon |
| 7 | Lebreton1, Helena Martini7, Henrik Salje5,8, Julie Toubiana1,2,9, Fekri Dureab10, Ghulam |
| 8 | Dhabaan11,* and Sylvain Brisse1,2,* |
| 9 | #The NCPHL diphtheria outbreak working group: Abdulaziz A. Rawah , Mohammed A. |
| 10 | Aldawla, Ekram M. Al-Awdi, Nabila M. Al-Moalmy, Khaled A. Almoayed, Huda Z. Al-Shami, Ali |
| 11 | A. Al-Somainy |
| 12 | Affiliations: |
| 13 | 1 Institut Pasteur, Biodiversity and Epidemiology of Bacterial Pathogens, Paris, France |
| 14 | 2 Institut Pasteur, National Reference Center for Corynebacteria of the diphtheriae complex, |
| 15 | Paris, France |
| 16 | 3 National Centre of the Public Health Laboratories (NCPHL), Sana'a, Yemen |
| 17 | 4 Hub de Bioinformatique et Biostatistique 🛛 Département Biologie Computationnelle, |
| 18 | Institut Pasteur, USR 3756 CNRS, Paris, France |
| 19 | 5 Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, UMR2000, CNRS, |
| 20 | Paris, France |
| 21 | 6 Sorbonne Université, Collège doctoral, F-75005 Paris, France |
| 22 | 7 Department of Microbiology, National Reference Centre for toxigenic corynebacteria, |
| 23 | Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, 1090 |
| 24 | Brussels, Belgium |
| 25 | 8 Department of Genetics, University of Cambridge, Cambridge, UK |
| 26 | 9 Université de Paris, General Paediatrics and Paediatric Infectious Diseases Department, |
| 27 | Hôpital Necker-Enfants malades, APHP, Paris, France |
| 28 | 10 Institute for Research in International Assistance, Akkon Hochschule, Berlin, Germany, 2- |
| 29 | Heidelberg Institute of Global Health, Heidelberg, Germany |
| 30 | 11 Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, Canada |
| 31 | *Correspondence: |

- 32 Sylvain Brisse. Institut Pasteur, Biodiversity and Epidemiology of Bacterial Pathogens, Paris,
- 33 France. E-mail: <u>sylvain.brisse@pasteur.fr</u>; Tel: +33 1 45 68 83 34;
- 34 Ghulam Dhabaan: Mount Sinai Hospital, University Health Network, University of Toronto,
- 35 Toronto, Canada. <u>Ghulam.Dhabaan@utoronto.ca</u>; Tel: +1 647 949 8012
- 36 Keywords: diphtheria, outbreak, epidemiology, phylogenetics, antimicrobial resistance,
- 37 genomic sequencing, evolutionary rate, Yemen
- 38 **Running Title**: Diphtheria in Yemen

39 Abstract

40 **Background**. An outbreak of diphtheria, declared in Yemen in October 2017, is still ongoing.

41 Methods. Probable cases were recorded through an electronic diseases early warning
42 system. Microbiological culture, genomic sequencing, antimicrobial susceptibility and toxin
43 production testing were performed.

44 Findings. The Yemen diphtheria outbreak developed in three epidemic waves, which 45 affected nearly all governorates (provinces) of Yemen, with 5701 probable cases and 330 deaths (October 2017 - April 2020). The median age of patients was 12 years (range, 0.17-46 47 80). Virtually all outbreak isolates (40 of 43 tested ones) produced the diphtheria toxin. We 48 observed low level of antimicrobial resistance to penicillin. We identified six separate 49 Corynebacterium diphtheriae phylogenetic sublineages, three of which are genetically 50 related to isolates from Saudi Arabia and Somalia. The predominant sublineage was resistant 51 to trimethoprim and was associated with unique genomic features, more frequent neck 52 swelling (p=0.002) and a younger age of patients (p=0.06). Its evolutionary rate was estimated at 1.67 x 10^{-6} substitutions per site year⁻¹, placing its most recent common 53 ancestor in 2015, and indicating silent circulation of *C. diphtheriae* in Yemen earlier than 54 55 outbreak declaration.

56 Interpretation. We disclose clinical, epidemiological and microbiological characteristics of 57 one of the largest contemporary diphtheria outbreaks and demonstrate clinically relevant 58 heterogeneity of *C. diphtheriae* isolates, underlining the need for laboratory capacity and 59 real-time microbiological analyses to inform prevention, treatment and control of 60 diphtheria.

Funding. This work was supported by institutional funding from the National Centre of the
Public Health Laboratories (Sanaa, Yemen) and Institut Pasteur (Paris, France) and by the
French Government Investissement d'Avenir Program.

64 Introduction

65 Diphtheria is a severe infection that typically affects the upper respiratory tract, potentially leading to pseudomembrane formation, neck swelling and suffocation [1, 2]. In addition, 66 67 diphtheria toxin production by some C. diphtheriae strains can cause damage to the heart 68 and other organs. Non-toxigenic strains can also cause invasive infections [3]. Before large 69 scale vaccination, which mainly targets the toxin and is highly effective in preventing the 70 disease, diphtheria was a major cause of death in children [2]. Large outbreaks of diphtheria 71 are often observed following disruption to vaccination programs, as occurred in the Soviet 72 Union in the 1990s [4] and more recently in the Rohingya refugee population in Bangladesh 73 [5] and in Venezuela [6]. Diphtheria is still observed occasionally in high-income countries, in 74 particular among migrants [7, 8].

75 In Yemen, where civil war has been raging since March 2015, a large outbreak of diphtheria 76 was recognized in October 2017 [9, 10][11]. While a vaccination campaign targeting 300,000 77 children began in late November 2018, with plans to scale up to 3 million children and young 78 adults in December, the ongoing conflict has complicated vaccination catch-up efforts [12, 13]. Before this outbreak, diphtheria was considered endemic in Yemen, with an average of 79 80 50 suspected cases reported annually since 2000 [14]. The last documented outbreak of 81 diphtheria in this country occurred in 1981-82, with a total of 149 cases with no death. 82 Yemen is currently also affected by other epidemic diseases including cholera [15] and 83 COVID-19 [16, 17]. As of May 2020, the diphtheria outbreak was still ongoing [18]. The early 84 epidemiology of the outbreak was described [9, 10], but virtually no data have been reported 85 on the clinical and microbiological characteristics of the outbreak.

86 Besides vaccination, a critical component of diphtheria management is serotherapy. 87 Unfortunately, diphtheria antitoxin is not readily available in Yemen, as in most world 88 countries [19]. Antimicrobial treatment is also indicated for patient care and to avoid 89 transmission, with penicillin and erythromycin being recommended as first-line therapeutic 90 agents [20][2].

91 Here we report on the clinical, epidemiological and microbiological features of the ongoing92 Yemen diphtheria outbreak.

93 Results

94 Epidemiology and clinical features of the Yemen diphtheria outbreak, 2017-2020

Large numbers of probable cases were recorded in 2017 (n=560), 2018 (n=2606), 2019
(n=2004) and in 2020 (up to week 17: n=649). Altogether, 5701 cases including 330 deaths
were reported up to April 26th, 2020, corresponding to a case fatality rate of 5.8%.

98 Between 2017 and 2020 there were three major waves of cases (Figure 1A). The first wave 99 occurred from October 2017 until June 2018 with a peak on week 6 of 2018. The second 100 wave was flatter and lasted from June 2018 until June 2019. The third wave started in June 101 2019 and reached its peak in October 2019, with more than 80 cases/week by that time.

102 The outbreak affected nearly all governorates of Yemen (Figure 1, Table S3). However, some 103 governorates were more affected and the two first epidemic waves had distinctive 104 geographic signatures (Figure 1D,E). The outbreak started in October 2017 in lbb, where 288 105 cases (52% of the total 2017 cases) were registered; while Al Hodeidah recorded 60 cases 106 (11%) in this year. In 2018, 2606 cases were registered in 21 governorates, with 64% of the 107 cases registered in 5 governorates: Hajja (395 cases, 15%), Al Hodeidah (338, 13%), Sana'a 108 (339, 13%), Ibb (324, 12%) and the capital city of Sana'a (276, 11%). Last, the distribution of 109 reported cases in 2019 shows that 60% of cases occurred in four governorates: Al Hodeida 110 (371 cases, 18%), Hajjah (327 cases, 16%), Sadah (297 cases, 15%) and Sana'a (226 cases, 111 11%).

112

113 Clinical data available for 888 patients (February 2018 - November 2019) showed that 114 patients were more likely to be female (55%), and their median age was 12 (range, 0-80) 115 years (Figure 2A). Of the 750 patients with available data, 434 (58%) reported a history of 116 previous vaccination against diphtheria. The vaccinated proportion of patients did not 117 change between 2018 and 2019 (57% vs. 59%, p=0.49). The median age of vaccinated 118 patients was lower (10 years, range 0.17-45) than that of non-vaccinated patients (13 years, 119 range 0.17-80; p<0.001). The age distribution of cases was available for the first two 120 epidemic waves. We found that the median age of infection was 12 years old; however, the 121 attack rate was highest in those 5-15 years in age as compared to other groups. While the 122 attack rate was largely constant between the first two years in those over 5 years old, there 123 was a marked reduction in children 0-4 years between the two waves (Figure 2B; Figure S1).

Almost all patients (n=818/841, 97%) had fever. Pseudomembrane was present in 787/839 (94%), signs of laryngitis in 548/784 (31%), neck swelling in 456/769 (59%) and tonsillitis in 821/836 (98%) patients with available data. Difficulty to swallow and to breathe were observed in 710 (86%) and 399 (51%) patients, respectively. No difference in disease expression was observed between vaccinated and non-vaccinated patients. Most patients (n=634/790, 80%) were reported to be under antibiotic therapy at the time of throat sampling.

131

Microbiological confirmation of cases was tested for 888 samples referred to the NCPHL from 2018 to 2020. Of the 836 cases with available results, 340 (41%) were microbiologically confirmed by a positive *C. diphtheriae* culture. The temporal and geographic distributions of tested and confirmed cases were similar (**Figure 1B-C**).

136

137 Phylogenetic diversity of *C. diphtheriae* from Yemen and their relationships with global

138 isolates

A random selection of 98 *C. diphtheriae* positive cultures were transferred to Institut Pasteur (Paris, France) for external confirmation and sequencing. Two cultures (YEM0065 = YE-NCPHL-647L) and YEM0070 = YE-NCPHL-647S) with distinct colony morphologies had been isolated from a single sample. We confirmed by qPCR [21] that 47 cultures carried genetic material of *C. diphtheriae*, 43 of which could be isolated in pure culture.

Detection of the diphtheria toxin *tox* gene was positive in 40 out of 43 isolates; 3 isolates were *tox*-negative by qPCR (**Table S1**), which was confirmed by genomic analyses. The Elek *in-vitro* test for diphtheria toxin production demonstrated that 39 *tox*-positive isolates produced the toxin (YEM0035 was Elek negative).

Phylogenomic analyses revealed the existence of six sublineages (labeled A to F, **Figure 3**). One of them, called sublineage A, comprised 30 (70%) isolates (**Table S1**). The six sublineages were unrelated to each other, as evidenced by their scattered positions in a global phylogenetic tree of *C. diphtheriae* (**Figure S2**), demonstrating multiple occurrences of diphtheria re-emergence or introductions into Yemen.

Sublineages A and B were of biovar Gravis, whereas the others were biovar Mitis. The detection of the *spuA* gene, coding for a putative alpha-1,6-glycosidase [22] associated with the glycogen positive phenotype of biovar Gravis, was consistent with these biochemical

assignations (Figure 3A) and showed that Yemen isolates belonged to two deep lineages of
 C. diphtheriae marked by the presence or absence of this gene (Figure S2) as recently
 reported [23].

159 Genotyping of the C. diphtheriae Yemen isolates by 7-gene multilocus sequence typing 160 (MLST, Table S1) revealed that sublineage A isolates belonged to ST384. The single 161 previously reported ST384 isolate (DIFT045; https://pubmlst.org/cdiphtheriae/) was isolated 162 in Belgium in 2016, and was collected in a patient who had close contact with a person 163 having traveled back from Saudi Arabia [24]. This observation hinted to a possible 164 epidemiological link between the main Yemen outbreak lineage and Saudi Arabia. To 165 reinforce this hypothesis, the genome of DIFT045 was sequenced, confirming its very close 166 genetic relatedness with sublineage A (Figure 3). Based on the global phylogenetic tree 167 (Figure S2), sublineage A was the Yemenite sublineage closest to the ex-Soviet Union 1990s 168 outbreak strain [25]. However, the large genetic distance between sublineage A isolates and 169 strain NCTC 13129, the reference for the ST8 ex-Soviet Union outbreak, rules out a direct 170 epidemiological link between the two outbreaks.

Sublineage E isolates were closely related to two isolates collected from migrants from Somalia [26], and sublineage C isolates were closely related to isolates from siblings with a Somalian origin [7]. Other Yemen sublineages were not phylogenetically closely related to isolates from previously sequenced *C. diphtheriae* isolates (**Figure S2**).

We defined the genomic diversity of Yemen and DIFT045 isolates by clustering their proteincoding genes (**Figure S3**). A total of 3619 gene families were identified, 1790 of which were shared by all isolates (core genome). Genomes had 2277 genes on average (range 2234-2427), and each of the six sublineages possessed 54 to 140 genes not observed in the other sublineages, underlying the potential for large phenotypic variation among them.

180

181 Microevolution of sublineage A

We subdivided sublineage A into two branches, with branch A.1 being further subdivided into A.1.1 and A.1.2 (Figure 3). The latter comprised the Belgium isolate DIFT045 and YEM0063. The epidemiologically predominant branch A.1 was highly homogeneous genetically, with a maximum of 86 genome-wide SNPs among its members (observed between YEM0063 and YEM0089), indicating that A.1 isolates share a recent common ancestor. The amount of nucleotide substitutions observed in isolates of this sublineage was

significantly related to their isolation time (Figure S4), demonstrating measurable evolutionary divergence (Figure 3B), with a substitution rate estimated at 1.67 x 10^{-6} substitutions per site per year (95%CI = $3.98 \times 10^{-7} - 2.99 \times 10^{-6}$). The last common ancestor of A.1.1 was estimated to have existed in March 2015 (Nov. 2003 - Sep. 2016). These results indicate that this subgroup of Yemenite diphtheria isolates circulated and diversified silently within the country several years before the diphtheria outbreak declaration in 2017.

194

195 Antimicrobial susceptibility of Yemen *C. diphtheriae* isolates

196 Antimicrobial susceptibility data were heterogeneous among Yemen sublineages (Figure 3, 197 Table S2). Importantly, full susceptibility or only low levels of penicillin resistance were 198 observed for all Yemen diphtheria isolates. While eight isolates (18.6%) were penicillin 199 resistant (Table S2), the two most resistant isolates had a minimal inhibitory concentration 200 (MIC) of 0.25 mg/L, which is only twice the clinical breakpoint of resistance (>0.125 mg/L). 201 Further, the MIC50 and MIC90 of penicillin were 0.094 and 0.19 mg/L, respectively (Table 202 52). Amoxicillin and erythromycin were also active against all isolates, as were many other tested molecules. Resistance to ciprofloxacin (but not to moxifloxacin) was observed in two 203 204 isolates, which had a D93G change in the quinolone-resistance determining region of their 205 gyrA gene. Resistance to trimethoprim was found in 32 (74.4%) isolates, including most 206 members of sublineage A (Figure 3), but none was resistant to the combination of this agent 207 with sulfamethoxazole (Table S2). Four isolates possessed homologs of the sul1 gene, and 208 decreased phenotypic susceptibility to sulfonamide was observed in two of these. Resistance 209 to tetracycline was observed in 11 isolates, which all belonged to minor sublineages whereas 210 sublineage A was susceptible (Figure 3A); five of these isolates possessed known tetracycline 211 resistance genes encoding the *tet33* efflux pump or the *tet0* ribosomal protection protein. 212 Finally, the two isolates of sublineage B possessed an *aadA2* gene coding for an ANT(3") 213 aminoglycoside modifying enzyme targeting spectinomycin and streptomycin. Accordingly, 214 these two isolates were susceptible to gentamicin and kanamycin.

215

Association of sublineage A with clinical signs and genomic features potentially linked tovirulence

218 Clinical features of *C. diphtheriae* infections caused by isolates from sublineage A were 219 distinctive, with patients tending to be younger (p=0.06) and with more frequent swollen

220 neck (p=0.002; **Table 1**). We screened the genomic sequences for the presence of putative 221 pathogenicity-associated genes. Sublineage A isolates possessed genes *iusABC* coding for an ABC-type iron uptake system, the chtAB genes that are homologous to htaAB genes for 222 223 hemin binding, a pathogenicity island of C. diphtheriae called PICD-11 [27] comprising a 224 putative collagen binding protein suggested to be associated with cutaneous or invasive 225 infections [28], and the spaABC-strA and spaDEF-strBC gene clusters coding for two distinct 226 types of fimbriae (Figure 3). In contrast to sublineage A, most other Yemen isolates did not 227 harbor the above gene clusters. In turn, their genomes comprised genes sidBA-ddpABC for 228 putative siderophore biosynthesis, *irp1ABCD* for a putative ABC-type iron transporter [29] 229 and the irp2ABCDEFGHI and irp2JKLMN operons. Genes coding for SpaH fimbriae were 230 absent from all Yemen genomes. Broader putative virulence genes variation was observed at 231 the global scale, with a marked dichotomy between the two major lineages defined by gene 232 spuA (Figure S2).

233 We further searched for sublineage A.1-enriched genes by analyzing the pangenome of 234 Yemen isolates together with the sublineage A-related strain NCTC13129. 77 genes were 235 enriched in sublineage A.1 (present in >95% A.1 isolates, and absent in >85% of other 236 isolates), among which six were uniquely found in all members of this sublineage (Table S4). 237 Among these, one gene was annotated as a 5-formyltetrahydrofolate cyclo-ligase gene, the 238 homolog of which was previously shown to increase the resistance level to antifolates in 239 Mycobacterium smegmatis and Escherichia coli [30]. Further analyses showed that this gene 240 is in fact found in all Corynebacterium genomes, but the sublineage A.1 version is shorter 241 (417 versus a median of 585 bp among all *Corynebacterium* species). Of note, the size of this 242 gene does not vary at all in C. diphtheriae except for isolates of the Yemen outbreak 243 sublineage A (585 bp). A possible causal link of this genetic truncation with resistance to 244 trimethoprim, which was observed mostly in sublineage A (but not solely A.1; Figure 3), will 245 be interesting to investigate in future studies.

246 **Discussion**

The outbreak of diphtheria in Yemen was first notified in October 2017 and its early epidemiology was described [9, 11, 14]. Here, we provide an update on the epidemiological situation, a clinical description of the characteristics of recorded suspected cases, and detailed information on microbiological features of *C. diphtheriae* outbreak isolates.

Based on currently reported probable cases, the Yemen diphtheria outbreak is one of the largest *C. diphtheriae* contemporaneous outbreaks. We identified three discernible waves with distinctive geographic signatures. We note that reporting is very likely to be an underestimate in the context of the Yemen health care disruption, and to be uneven geographically given the heterogeneity in the continuation of health care facility operations. Nevertheless, the eDEWS system [31] proved invaluable in the surveillance of diphtheria in the conflict context.

258 Clinical characteristics were typical of diphtheria in terms of laryngeal manifestations, 259 pseudomembrane presence and neck swelling [32]. Yemenite patients were mostly young, 260 which is also typical, with the exception of the ex-Soviet Union event [4]. Vaccination is 261 highly effective against the clinical expression of toxigenic C. diphtheriae infections, and 262 countries with high population coverage have virtually eliminated endemic diphtheria [2]. In 263 Yemen, the vaccination coverage of the third dose of pentavalent vaccine in 2017 and 2018 264 (Figure S5) was <80% in several governorates, which is considered as insufficient to reach 265 population immunity [33]. We found that more than 50% of patients were reported to be 266 previously vaccinated. We did not have access to the exact vaccination status, but we can 267 assume that this observation reflects an incomplete vaccination without booster. This might 268 also explain the median age > 5 years of patients, comparable to other outbreaks in 269 populations where vaccination was incomplete [34][35]. From November 2017 to March 270 2018, a mass vaccination campaign targeted nearly 2.7 million children aged 6 weeks to 15 271 years in 11 governorates [36]. Here we found that from the first to the second wave, there 272 was a reduction in infection risk in 0-4 years old, consistent with some success from the 273 mass immunization program. In 2019, diphtheria vaccination was further conducted in 186 274 districts of the 12 Northern governorates [37], with 1.2 million children 6 weeks to 5 years of 275 age vaccinated with the Penta vaccine and 2.2 million children 5-15 years with the Td 276 vaccine. Vaccination against diphtheria in selected districts of Southern governorates and

277 Sa'adah has started in July 2020. However, despite efforts to control the disease, cases were 278 still being reported in 2020, and future studies will be needed to evaluate their effect.

279 This work represents a unique genomic analysis of a large contemporaneous outbreak of 280 diphtheria. A prominent observation was that at least six phylogenetic sublineages, 281 ancestrally unrelated within the global diversity of C. diphtheriae, contributed to the 282 resurgence of diphtheria in Yemen. This important observation shows that strains with 283 distinctive genomic and phenotypic characteristics can coexist within a single diphtheria 284 outbreak. The multiplicity of strains reflects a silent diversity reservoir of C. diphtheriae 285 despite vaccination, which is designed to protect against disease expression rather than 286 colonization and transmission. Antimicrobial resistance remains rare in *C. diphtheriae* [38], 287 and our results show that the main recommended agents (penicillin G, aminopenicillin and 288 erythromycin) are active against Yemen C. diphtheriae despite a low-level penicillin 289 resistance in some isolates. However, antimicrobial susceptibility profiles were 290 heterogeneous, with a strong phylogenetic sublineage effect, and were largely concordant 291 with genomic data, implying a possible future role for molecular testing of antimicrobial 292 resistance in *C. diphtheriae*.

293 Our work also uncovers a large heterogeneity in virulence-associated genomic features 294 among circulating isolates. The diphtheria toxin gene was observed in most isolates, which 295 were all confirmed to produce the toxin *in vitro* except one, which was non-toxigenic toxin 296 gene bearing (NTTB). However, three isolates were tox-negative, indicating that such isolates 297 can cause diphtheria-like respiratory symptoms. Currently, with the important exception of 298 diphtheria toxin, the links between virulence genes of C. diphtheriae strains and clinical 299 expression are unknown [39]. Whereas two Yemen sublineages are of biovar Gravis, four 300 were of biovar Mitis. Biovar Gravis isolates have been considered more virulent than biovar 301 Mitis isolates [40, 41]. Interestingly, our work reveals that the distribution of virulence-302 associated genes is strongly contrasted between two major lineages of C. diphtheriae, which 303 were defined here by the presence of the Gravis-specific gene spuA. Our genomic data 304 suggest that inter-lineage heterogeneity in iron acquisition, adhesion and colonization 305 capacities may exist and could underlie epidemiological or clinical differences among them. 306 We found that patients infected with sublineage A, of biovar Gravis, tended to be younger 307 and with more frequent neck swelling. However, as neck swelling is more commonly 308 observed in young patients, we cannot disentangle sublineage and age effects here. The

309 underlying mechanisms of lymph node manifestations in diphtheria, described as nonspecific 310 acute lymphadenitis [1], are unknown. Future studies should investigate the impact of the 311 genomic diversity of *C. diphtheriae* on the pathogenicity and clinical expression of 312 diphtheria.

313 Genomic sequencing of bacterial pathogens is a powerful approach to define relationships 314 across time, sources and geography [42][15]. The C. diphtheriae genotypes observed in 315 Yemen were distinct from strains from the large ex-Soviet Union 1990s outbreak, whereas 316 no data exists on the strains involved in other recent outbreaks in Venezuela, Haiti and 317 Bangladesh. Migration and trade from the horn of Africa into Yemen are major drivers of 318 pathogenic strain spread, as observed for cholera [15]. The nearly complete lack of 319 information on circulating C. diphtheriae from neighboring countries has restricted our 320 ability to define the dynamics of geographic spread of *C. diphtheriae* in this world region. 321 However, a few *C. diphtheriae* genomes were linked epidemiologically and genetically to the 322 neighboring countries Somalia and Saudi Arabia.

323 We estimated the evolutionary rate of C. diphtheriae and found it is similar to other human 324 pathogens sampled over short time scales, such as Staphylococcus aureus or Streptococcus 325 pyogenes [43]. Our genomic data analyses thus imply that the diversification of the major 326 Yemen outbreak sublineage largely predates the detection of the outbreak by the disease 327 surveillance system. These observations concur with the multiplicity of sublineages that a 328 reservoir of C. diphtheriae diversity existed in Yemen before the outbreak recognition. We 329 note that our rate and age estimates have large confidence intervals, which is explained by 330 the small number of available genomes.

Although we provide a glimpse into the microbiological characteristics of diphtheria in Yemen, the available samples of *C. diphtheriae* sent for biological confirmation currently do not provide a complete picture of the outbreak. Samples referred to NCPHL were distributed across a large time period but governorates of the Southern part of the country were largely under-represented, as 91% of confirmed samples came from Northern governorates (**Table S3**). This limitation reflects the current situation of the country, divided by conflict into South and North parts.

In summary, this work sheds light on epidemiological and clinical aspects of the current
Yemen diphtheria outbreak. We demonstrate high phylogenetic, genomic and phenotypic
variation of *C. diphtheriae* within a single outbreak, suggesting that the characterization of

341 isolates at the level of individual patients or local chains of transmission is relevant for 342 patient management during diphtheria outbreaks. This underlines the need to reinforce 343 laboratory capacity in the context of diphtheria outbreaks. Concerted international efforts 344 should be developed aiming at enhancing surveillance and defining in real time the 345 characteristics of C. diphtheriae clinical isolates. Diphtheria is a largely forgotten disease, and 346 contemporaneous research into its pathophysiology is scarce. Further, in face of increasing 347 disruption of vaccination campaigns and the shortage of diphtheria antitoxin supply, studies 348 into the determinants of local persistence of *C. diphtheriae* and its spread at regional or 349 global scales are needed in order to better control the reemergence of this dreadful 350 pathogen.

351 Methods

352 Definitions and surveillance data

Probable cases were defined based on clinical examination: any person with illness 353 354 characterized by an adherent membrane on the tonsils, pharynx and/or nose and any one of 355 the following: laryngitis, pharyngitis or tonsillitis [31]. Confirmed cases were defined as a 356 probable case from which a C. diphtheriae isolate was cultivated in the NCPHL laboratory. 357 Probable cases were based on the health facility surveillance system and were compiled 358 from electronic diseases early warning system (eDEWS) releases of weekly reporting of diphtheria cases [31]. For the vaccination coverage, we used the 2017 and 2018 annual 359 360 reports by the national Expanded Programme on Immunization (EPI), obtained from the 361 Ministry of Public Health and Population (MoPHP) of Yemen. The attack rate per age group 362 was calculated by dividing the number of cases of each age group by the size of the 363 population within each age group (source: https://www.census.gov/data-364 tools/demo/idb/informationGateway.php).

365

366 Biological confirmation, clinical data and external microbiological and genomic analyses

A total of 888 throat swab samples were received by the NCPHL and analyzed using local microbiological procedures (Supplementary data). Demographic data, prior vaccination, signs and symptoms and current antibiotic of patients were collected for all samples. A random selection of 98 samples available on July 2019 was sent to Institut Pasteur for external analyses (Supplementary data).

372

Data availability

The whole genome sequencing data generated in this study were deposited in the European Nucleotide Archive (ENA) database and are accessible through the study PRJEB34206 (https://www.ebi.ac.uk/ena/data/view/PRJEB34206). Raw read data are available under the accessions ERR4332853-96. Contig sequences are available under the accessions CAJDXH01000000-CAJDYY01000000.

379 Ethical statement

380 Data were collected as part of routine case management under an emergency response 381 mandate from the government of Yemen. The scientific committee of the NCPHL, Sana'a 382 authorized the usage of the clinical data included in this study.

383 Author contributions

384 A.H., the NCPHL diphtheria outbreak working group (A.A.R, M.A.A., E.M.A.-A., N.M.A.-M., 385 K.A.A, H.Z. A.-S., A.A.A.-S.), A.C-L., E.B., M.P.P. and M.L. performed the microbiological 386 cultures of the isolates and their biochemical and molecular characterizations. F.D., G.D., 387 N.L. and H.S. collated and analyzed the epidemiological data. A.H., G.D. and J.T. collated and 388 analyzed the clinical data. A.C., V.B., M.H., J.G., N.Z. and S.B. analyzed the genomic data. 389 H.M. provided the DIFT045 strain. S.B. and G. D. initially designed, and subsequently 390 coordinated, the project. S.B. designed the microbiological aspects of the study and wrote 391 the initial version of the manuscript. All authors provided input to the manuscript and 392 reviewed the final version.

393 Conflicts of interests

394 The authors declare no competing interests.

395 Acknowledgments

We thank Dr Taha Almotuakel (Yemen Ministry of Health) for continuous support, and Isabelle Cailleau (Institut Pasteur) and the Medecins Sans Frontieres Organization for logistical support. The NCPHL also acknowledges the World Health Organization for providing some reagents used in this study. This work used the computational and storage services (TARS cluster) provided by the IT department at Institut Pasteur.

401 Role of the funding source

402 This work was supported financially by institutional funding from the NCPHL-Sana'a and 403 Institut Pasteur. The French National Reference Center for Corynebacteria of the diphtheriae 404 complex received support from Institut Pasteur and Public Health France (Santé publique 405 France, Saint Maurice, France). This work was also supported financially by the French 406 Government's Investissement d'Avenir program Laboratoire d'Excellence "Integrative 407 Biology of Emerging Infectious Diseases" (ANR-10-LABX-62-IBEID). The funders had no role 408 in the study design, collection, analysis, interpretation of the data and manuscript writing. 409 Institut Pasteur and the NCPHL supported the decision to submit the paper for publication.

410 Figure Legends

411 Figure 1. Epidemic curve and geographic and temporal origins of the isolates.

412 A. Weekly numbers of suspected cases (purple), samples (light blue) and confirmed isolates 413 (dark blue) of diphtheria in Yemen from January 2017 to April 2020, with three epidemic 414 waves being highlighted. Sequenced isolates are shown below the epidemic curve, colored 415 according to their sublineages (see Figure 3). B and C. Geographical location of the 888 416 samples of this study (B) and of the 340 confirmed samples (C). D and E. Geographical 417 location of the suspected cases during the first epidemic wave (D) and the second epidemic 418 wave (E). The governorate maps of Yemen was created using a shape file approved by the 419 Humanitarian Country Team in October 2019 (https://data.humdata.org/dataset/yemen-420 admin-boundaries).

421

422 Figure 2. Age profile of suspected cases.

423 A. Age distribution of suspected cases during the first and second waves. B. Attack rates per

424 age group, per wave. Red shows the first wave, green the second. The mean attack rate

- 425 during the two waves was 6.6 per 100,000.
- 426

427 Figure 3. Phylogenetic analysis of Yemen isolates with their virulence and resistance

428 characteristics.

429 A. Phylogenetic tree of the Yemen isolates, with the distinction of 6 sublineages (A to F; 430 sublineage A was subdivided into A.1 [A.1.1, A.1.2] and A.2). On the right of the tree, the 431 black squares denote a resistance phenotype, while a black circle denote the presence of the 432 tox-gene or other virulence-associated genes. Open squares denote an intermediate 433 resistance phenotype. Scale bar, 0.001 nucleotide substitutions per site. B. Detailed 434 phylogenetic tree of the sublineage A. Nodes' ages and 95%CI are shown at the nodes. Scale bar, 0.000005 nucleotide substitutions per site (*i.e.*, 1 substitution every 200,000 435 436 nucleotides, or approximately 10 substitutions per genome).

437 **References**

- Hadfield TL, McEvoy P, Polotsky Y, Tzinserling VA, Yakovlev AA. The pathology of diphtheria. J
 Infect Dis 2000;181 Suppl 1:S116-120.
- 440
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
 441
- 442 3. Patey O, Bimet F, Riegel P, Halioua B, Emond JP, *et al.* Clinical and molecular study of
 443 Corynebacterium diphtheriae systemic infections in France. Coryne Study Group. *J Clin Microbiol* 444 1997;35:441–445.
- 44. Dittmann S, Wharton M, Vitek C, Ciotti M, Galazka A, *et al.* Successful control of epidemic
 diphtheria in the states of the Former Union of Soviet Socialist Republics: lessons learned. J
 447 Infect Dis 2000;181 Suppl 1:S10-22.
- 4485.Rahman MR, Islam K. Massive diphtheria outbreak among Rohingya refugees: lessons learnt. J449Travel Med;26. Epub ahead of print 1 January 2019. DOI: 10.1093/jtm/tay122.
- 450 6. Paniz-Mondolfi AE, Tami A, Grillet ME, Márquez M, Hernández-Villena J, *et al.* Resurgence of
 451 Vaccine-Preventable Diseases in Venezuela as a Regional Public Health Threat in the Americas.
 452 *Emerg Infect Dis* 2019;25:625–632.
- 453 7. Meinel DM, Kuehl R, Zbinden R, Boskova V, Garzoni C, et al. Outbreak investigation for
 454 toxigenic Corynebacterium diphtheriae wound infections in refugees from Northeast Africa and
 455 Syria in Switzerland and Germany by whole genome sequencing. Clin Microbiol Infect Off Publ
 456 Eur Soc Clin Microbiol Infect Dis 2016;22:1003.e1-1003.e8.
- 457 8. Scheifer C, Rolland-Debord C, Badell E, Reibel F, Aubry A, *et al.* Re-emergence of
 458 Corynebacterium diphtheriae. *Med Mal Infect* 2019;49:463–466.
- 459 9. Dureab F, Müller O, Jahn A. Resurgence of diphtheria in Yemen due to population movement. J
 460 Travel Med;25. Epub ahead of print 1 January 2018. DOI: 10.1093/jtm/tay094.
- 461 10. Dureab F, Al-Sakkaf M, Ismail O, Kuunibe N, Krisam J, et al. Diphtheria outbreak in Yemen: the
 462 impact of conflict on a fragile health system. *Confl Health* 2019;13:19.
- 463 11. WHO. Diphtheria Yemen. *Disease Outbreak News*. https://www.who.int/csr/don/22 464 december-2017-diphtheria-yemen/en/ (2017).
- 465 12. OCHA. Yemen: Diphtheria Outbreak Nov 2017. https://reliefweb.int/disaster/ep-2017-000175466 yem (2017).
- 467 13. Meyer D. Yemen-- First cholera, now diphtheria.
- 468https://www.outbreakobservatory.org/outbreakthursday-1/11/30/2017/yemen-first-cholera-469now-diphtheria (2017).
- 470 14. WHO-EMRO. Weekly Epidemiological Monitor, Volume 10, Issue 47 (19 November 2017).
 471 https://reliefweb.int/report/yemen/who-emro-weekly-epidemiological-monitor-volume-10issue-47-19-november-2017 (2017).
- 473 15. Weill F-X, Domman D, Njamkepo E, Almesbahi AA, Naji M, *et al.* Genomic insights into the
 474 2016-2017 cholera epidemic in Yemen. *Nature* 2019;565:230–233.

- 475 16. Dureab F, Al-Awlaqi S, Jahn A. COVID-19 in Yemen: preparedness measures in a fragile state.
 476 Lancet Public Health 2020;5:e311.
- 477 17. Dhabaan GN, Al-Soneidar WA, Al-Hebshi NN. Challenges to testing COVID-19 in conflict zones:
 478 Yemen as an example. *J Glob Health* 2020;10:010375.
- 479 18. eDEWS. Electronic Integrated Disease Early Warning and Response System, Volume 08, Issue19,
 480 Epi week 19,(04- 10 May,2020).
- 481
 482
 482
 483
 483
 484
 484
 485
 485
 486
 486
 487
 488
 488
 489
 480
 480
 480
 480
 480
 481
 481
 482
 483
 483
 483
 484
 484
 485
 485
 486
 486
 487
 487
 488
 488
 488
 488
 488
 489
 480
 480
 480
 480
 480
 480
 480
 481
 481
 482
 482
 483
 483
 483
 483
 484
 484
 484
 485
 485
 485
 485
 486
 486
 487
 487
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
- 484 20. **Kneen R, Pham NG, Solomon T, Tran TM, Nguyen TT,** *et al.* Penicillin vs. erythromycin in the 485 treatment of diphtheria. *Clin Infect Dis Off Publ Infect Dis Soc Am* 1998;27:845–850.
- 486
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
- 488 22. Santos AS, Ramos RT, Silva A, Hirata R, Mattos-Guaraldi AL, *et al.* Searching whole genome sequences for biochemical identification features of emerging and reemerging pathogenic Corynebacterium species. *Funct Integr Genomics* 2018;18:593–610.
- 491 23. Hennart M, Panunzi LG, Rodrigues C, Gaday Q, Baines SL, *et al.* Population genomics and
 492 antimicrobial resistance in Corynebacterium diphtheriae. *bioRxiv* 2020;2020.05.19.101030.
- 493 24. Martini H, Soetens O, Litt D, Fry NK, Detemmerman L, et al. Diphtheria in Belgium: 2010-2017. J
 494 Med Microbiol 2019;68:1517–1525.
- 495 25. Cerdeño-Tárraga AM, Efstratiou A, Dover LG, Holden MTG, Pallen M, *et al.* The complete
 496 genome sequence and analysis of Corynebacterium diphtheriae NCTC13129. *Nucleic Acids Res*497 2003;31:6516–6523.
- 498 26. Berger A, Dangel A, Schober T, Schmidbauer B, Konrad R, et al. Whole genome sequencing suggests transmission of Corynebacterium diphtheriae-caused cutaneous diphtheria in two
 500 siblings, Germany, 2018. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull;24. Epub ahead of print January 2019. DOI: 10.2807/1560-7917.ES.2019.24.2.1800683.
- 502 27. Trost E, Tauch A. Comparative genomics and pathogenicity islands of Corynebacterium
 503 diphtheriae, Corynebacterium ulcerans, and Corynebacterium pseudotuberculosis. In:
 504 Corynebacterium diphtheriae and related toxigenic species: genomics, pathogenicity and
 505 applications. Burkovski, A. Ed.; Springer; 2014. pp. 39–65.
- 506 28. Timms VJ, Nguyen T, Crighton T, Yuen M, Sintchenko V. Genome-wide comparison of
 507 Corynebacterium diphtheriae isolates from Australia identifies differences in the Pan-genomes
 508 between respiratory and cutaneous strains. *BMC Genomics* 2018;19:869.
- S09 29. Qian Y, Lee JH, Holmes RK. Identification of a DtxR-regulated operon that is essential for
 siderophore-dependent iron uptake in Corynebacterium diphtheriae. *J Bacteriol* 2002;184:4846–
 511 4856.
- 512 30. **Ogwang S, Nguyen HT, Sherman M, Bajaksouzian S, Jacobs MR**, *et al.* Bacterial conversion of folinic acid is required for antifolate resistance. *J Biol Chem* 2011;286:15377–15390.

- 514 31. Dureab F. The usefulness of the electronic Disease Early Warning System (eDEWS) in the
- 515 *humanitarian crisis of Yemen*. University of Heidelberg. https://archiv.ub.uni-
- 516 heidelberg.de/volltextserver/27986/ (2019).
- 517 32. Dash N, Verma S, Jayashree M, Kumar R, Vaidya PC, *et al.* Clinico-epidemiological profile and
 518 predictors of outcome in children with diphtheria: a study from northern India. *Trop Doct* 519 2019;49:96–101.
- 33. Blumberg LH, Prieto MA, Diaz JV, Blanco MJ, Valle B, et al. The Preventable Tragedy of
 Diphtheria in the 21st Century. International journal of infectious diseases 2: IJID2: official
 publication of the International Society for Infectious Diseases;71. Epub ahead of print June 2018.
 DOI: 10.1016/j.ijid.2018.05.002.
- 52434. Murhekar M. Epidemiology of Diphtheria in India, 1996-2016: Implications for Prevention and525Control. Am J Trop Med Hyg 2017;97:313–318.
- 526 35. Galazka A. The changing epidemiology of diphtheria in the vaccine era. J Infect Dis 2000;181
 527 Suppl 1:S2-9.
- 528 36. OCHA-services. Diphtheria vaccination campaign for 2.7 million children concludes in Yemen.
 529 https://reliefweb.int/report/yemen/diphtheria-vaccination-campaign-27-million-children 530 concludes-yemen (2018).
- 531 37. WHO-EMRO. Situation Report, September 2019, Issue NO.9: Yemen Conflict.
 532 https://reliefweb.int/sites/reliefweb.int/files/resources/Yem-Sitrep-Sept-2019.pdf (2019).
- 533 38. Zasada AA. Antimicrobial susceptibility and treatment. In: Corynebacterium diphtheriae and
 534 related toxigenic species genomics, pathogenicity and applications. Burkovski A., editor. New
 535 York: Springer; 2014. pp. 239–246.
- 536 39. Sangal V, Hoskisson PA. Evolution, epidemiology and diversity of Corynebacterium diphtheriae:
 537 New perspectives on an old foe. *Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis* 538 2016;43:364–370.
- 40. McLeod JW. THE TYPES MITIS, INTERMEDIUS AND GRAVIS OF CORYNEBACTERIUM DIPHTHERIAE:
 540 A Review of Observations during the Past Ten Years. *Bacteriol Rev* 1943;7:1–41.
- 541 41. Barksdale L. Corynebacterium diphtheriae and its relatives. *Bacteriol Rev* 1970;34:378–422.
- 542 42. Moura A, Criscuolo A, Pouseele H, Maury MM, Leclercq A, et al. Whole genome-based
 543 population biology and epidemiological surveillance of Listeria monocytogenes. Nat Microbiol
 544 2016;2:16185.
- 545 43. Duchêne S, Holt KE, Weill F-X, Le Hello S, Hawkey J, *et al.* Genome-scale rates of evolutionary
 546 change in bacteria. *Microb Genomics* 2016;2:e000094.
- 547

548 Table 1. Clinical characteristics of patients infected by sublineage A or other sublineages

549 circulating in Yemen

| Characteristics, (%) otherwise stated | Sublineage A | Other sublineages | P value* |
|---------------------------------------|--------------|-------------------|----------|
| | N=28 | N=14 | |
| Age, years, median (range) | 8 (2-35) | 14 (2-35) | 0.06 |
| Male | 14 (50) | 5 (36) | 0.38 |
| History of previous vaccination | 11 (44) | 7 (64) | 0.24 |
| Fever | 28 (100) | 14 (100) | - |
| Pseudomembrane | 28 (100) | 14 (100) | |
| Neck swelling | 22 (84) | 4 (33) | 0.002 |

* Differences between cases infected with *C. diphtheriae* sublineage A compared to the ones

infected with isolates from other sublineages (B, C, D, E or F) were assessed by the Mann-

552 Whitney U test, the Student's t test, the χ^2 method, and Fisher's exact test where

553 appropriate.



0 100

200

300 400km

Number of samples 800 600 400 200 0

no data

Number of suspected cases

| 5 00 |
|-------------|
| 400 |
| 300 |
| 200 |
| 100 |
| 0 |
| no data |



